PPD, Inc. provides drug development services to the biopharmaceutical industry, focuses on helping customers bring their new medicines to patients around the world. The firm also provides clinical development and laboratory services to pharmaceutical, biotechnology, medical device and government organizations and other industry participants. Its clinical development services include all phases of development (Phase I-IV), peri- and post-approval and site and patient access services; laboratory services offers advanced testing services, including bioanalytical, biomarker, vaccine, good manufacturing practice and central laboratory services. The company was founded by Fred Eshelma in 1985 and is headquartered in Wilmington, NC.

$46.11  -0.01 (-0.02%)
As of 05/11/2021 15:59:59 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Large cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—Specialty &
Index country:  USA
Country of incorporation:  USA
IPO date:  12/31/1997
Outstanding shares:  350,976,576
Average volume:  7,867,964
Market cap:   $16,180,020,154
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    69355F102
ISIN:        US69355F1021
Sedol:      BL9BT47
Valuation   (See tab for details)
PE ratio:   85.01
PB ratio:   -25.29
PS ratio:   3.24
Return on equity:   -33.65%
Net income %:   4.32%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy